
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen Inc is gearing up for a strategic product launch of PRGN-2012 in the second half of 2025, supported by upgraded GMP facilities aimed at enhancing manufacturing capacity, which positions the company for effective supply management at the time of launch. Management's proprietary market analysis projects significant revenue growth for PRGN-2012, estimating risk-adjusted revenues of $93 million in 2026, which could increase to approximately $969 million by 2033, demonstrating strong potential market demand. With adjustments to operational models reflecting a larger projected patient population and increased annual pricing estimates for PRGN-2012, Precigen is poised for a robust market entry and adoption, backed by strong Phase 2 data indicating a favorable outlook for the company's future revenues.
Bears say
Precigen Inc's financial performance has been adversely affected by a series of operational challenges that hinder the commercialization of its synthetic biology solutions, particularly within its Biopharmaceuticals segment. The company's reliance on external collaborators for compensation and funding has resulted in inconsistent revenue streams, which raises concerns about its ability to sustain long-term growth and profitability. Additionally, the lack of clear paths to market for many of its technologies and the competitive landscape in the biotechnology sector contribute to a negative outlook for Precigen's stock.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares